Defibrotide for Patients with Hepatic Veno-Occlusive Disease

Full Title

Defibrotide for Patients with Hepatic Veno-Occlusive Disease(VOD): A Treatment IND Study


Veno-occlusive disease (VOD) is an inflammatory condition caused by the high-dose chemotherapy used to condition patients before stem cell transplants. The therapy damages blood vessels and cells in the liver and leads to pain, build up of fluid in the body, and abnormal liver function.

Defibrotide is an investigational drug being studied as a possible treatment for VOD. Defibrotide has been used in the past to treat kidney loss after kidney transplantation, to lower blood vessel inflammation, and to treat VOD in blood stem cell transplant patients. These studies show that defibrotide cures severe VOD in about 40 percent of patients. The purpose of this study is to evaluate the safety and effectiveness of defibrotide as a possible treatment for VOD.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patient must have a diagnosis of veno-occlusive disease.

For more information and to inquire about eligibility for this study, please contact Dr. Nancy A. Kernan at 212-639-7250.